$ALDX
Aldeyra Therapeutics, Inc.

2018 Q2 Form 10-Q Financial Statement

#000119312518164070 Filed on May 15, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2018 Q1 2017 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.370M $1.890M $1.730M
YoY Change 60.14% 9.25% 18.49%
% of Gross Profit
Research & Development $6.793M $6.600M $3.369M
YoY Change 76.49% 95.91% -4.06%
% of Gross Profit
Depreciation & Amortization $20.00K $11.41K $9.660K
YoY Change 100.0% 18.07% 19.23%
% of Gross Profit
Operating Expenses $6.793M $6.600M $3.369M
YoY Change 76.49% 95.91% -4.06%
Operating Profit -$9.166M -$8.491M -$5.096M
YoY Change 71.95% 66.63% 2.59%
Interest Expense $26.36K $28.04K $26.84K
YoY Change -0.4% 4.5% 7.2%
% of Operating Profit
Other Income/Expense, Net $115.6K $94.35K $4.780K
YoY Change 427.34% 1873.77% -1612.66%
Pretax Income -$9.050M -$8.397M -$5.090M
YoY Change 70.44% 64.97% 2.41%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$9.050M -$8.397M -$5.091M
YoY Change 70.48% 64.94% 2.49%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$458.0K -$433.7K -$368.8K
COMMON SHARES
Basic Shares Outstanding 20.11M shares 19.66M shares 15.13M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $41.70M $38.90M $31.20M
YoY Change 61.63% 24.68% 35.65%
Cash & Equivalents $24.61M $20.96M $12.02M
Short-Term Investments $17.10M $18.00M $11.90M
Other Short-Term Assets $1.400M $1.700M $300.0K
YoY Change 180.0% 466.67% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $43.07M $40.61M $31.47M
YoY Change 63.51% 29.01% 35.02%
LONG-TERM ASSETS
Property, Plant & Equipment $214.7K $170.9K $58.28K
YoY Change 347.56% 193.15% -28.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets $214.7K $170.9K $58.28K
YoY Change 70.54% 193.15% -54.27%
TOTAL ASSETS
Total Short-Term Assets $43.07M $40.61M $31.47M
Total Long-Term Assets $214.7K $170.9K $58.28K
Total Assets $43.29M $40.78M $31.53M
YoY Change 63.54% 29.32% 34.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $802.1K $1.619M $694.9K
YoY Change 5.17% 132.96% 20.23%
Accrued Expenses $4.159M $1.815M $1.520M
YoY Change 300.33% 19.41% 46.77%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $349.0K $232.6K $193.9K
YoY Change 12.5% 20.0% 0.0%
Total Short-Term Liabilities $5.310M $3.667M $2.409M
YoY Change 151.46% 52.21% 33.26%
LONG-TERM LIABILITIES
Long-Term Debt $995.3K $1.108M $1.128M
YoY Change -2.07% -1.75% 2.32%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $995.3K $1.108M $1.128M
YoY Change -2.07% -1.75% 2.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.310M $3.667M $2.409M
Total Long-Term Liabilities $995.3K $1.108M $1.128M
Total Liabilities $6.305M $4.775M $3.537M
YoY Change 101.57% 35.01% 21.54%
SHAREHOLDERS EQUITY
Retained Earnings -$117.1M -$108.0M -$82.39M
YoY Change 33.51% 31.13% 29.61%
Common Stock $154.1M $144.1M $110.4M
YoY Change 38.75% 30.5% 31.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $36.98M $36.00M $28.00M
YoY Change
Total Liabilities & Shareholders Equity $43.29M $40.78M $31.53M
YoY Change 63.54% 29.32% 34.54%

Cashflow Statement

Concept 2018 Q2 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$9.050M -$8.397M -$5.091M
YoY Change 70.48% 64.94% 2.49%
Depreciation, Depletion And Amortization $20.00K $11.41K $9.660K
YoY Change 100.0% 18.07% 19.23%
Cash From Operating Activities -$6.250M -$7.955M -$4.190M
YoY Change 17.7% 89.85% -6.47%
INVESTING ACTIVITIES
Capital Expenditures -$60.00K $139.0K $11.59K
YoY Change 1099.15% 25.54%
Acquisitions
YoY Change
Other Investing Activities $920.0K $4.940M $900.0K
YoY Change 41.54% 448.89%
Cash From Investing Activities $860.0K $4.801M $890.0K
YoY Change 32.31% 439.49% -9000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $3.200M $4.093M $10.58M
YoY Change -61.32%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.030M 4.093M 10.58M
YoY Change -30200.0% -61.31% -105900.0%
NET CHANGE
Cash From Operating Activities -6.250M -7.955M -4.190M
Cash From Investing Activities 860.0K 4.801M 890.0K
Cash From Financing Activities 9.030M 4.093M 10.58M
Net Change In Cash 3.640M 940.2K 7.280M
YoY Change -177.61% -87.09% -261.78%
FREE CASH FLOW
Cash From Operating Activities -$6.250M -$7.955M -$4.190M
Capital Expenditures -$60.00K $139.0K $11.59K
Free Cash Flow -$6.190M -$8.094M -$4.202M
YoY Change 16.57% 92.63% -6.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20109394 shares
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19302850
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1815428
CY2018Q1 us-gaap Assets Current
AssetsCurrent
40605039
CY2018Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
37592749
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
144036909
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1618889
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16385
CY2018Q1 us-gaap Assets
Assets
40775901
CY2018Q1 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
17974600
CY2018Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
34990985
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20963541
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19664921 shares
CY2018Q1 us-gaap Cash
Cash
1345392
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19664921 shares
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
19665
CY2018Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
435448
CY2018Q1 us-gaap Liabilities
Liabilities
4774697
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40775901
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3666956
CY2018Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2018Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
232639
CY2018Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1107741
CY2018Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
2618149
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
7.00
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.50
CY2018Q1 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1063004
CY2018Q1 aldx Fair Value Of Warrant Issued
FairValueOfWarrantIssued
266000
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1666898
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
170862
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108038985
CY2018Q1 us-gaap Securities For Reverse Repurchase Agreements
SecuritiesForReverseRepurchaseAgreements
17000000
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3866261
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6037040
CY2018Q1 us-gaap Share Price
SharePrice
7.50
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1296368 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.62
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3066856 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.84
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
36001204
CY2018Q1 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
17990985
CY2018Q1 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
316976
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1100000 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
19138
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
788570
CY2017Q4 us-gaap Liabilities
Liabilities
4573939
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44174958
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3353747
CY2017Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
116319
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1220192
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
211528 shares
CY2015Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
9.33
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12015061
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2236465
CY2017Q4 us-gaap Assets Current
AssetsCurrent
43965766
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
41967314
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
139241635
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1000963
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-17831
CY2017Q4 us-gaap Assets
Assets
44174958
CY2017Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
22923462
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20023337
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19137639 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19137639 shares
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1018967
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43262
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99641923
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2246857 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.87
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
39601019
CY2017Q4 aldx Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
165930
CY2017Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1327103
CY2017Q4 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
120792
CY2015Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7100000
CY2015Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1100000 shares
CY2015Q1 invest Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
0.125
CY2015Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1900000
CY2015Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
211528 shares
CY2015Q1 aldx Class Of Warrant Or Rights Expire Month Year
ClassOfWarrantOrRightsExpireMonthYear
2018-01
CY2018Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3200000
CY2018Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
444000 shares
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4100000
CY2018Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
527000 shares
CY2017Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
5196
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
858096
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3786631 shares
CY2017Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-79775
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7287789
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5095997
CY2017Q1 us-gaap Depreciation
Depreciation
9660
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1726878
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-425929
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
419481
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
42001
CY2017Q1 us-gaap Interest Expense
InterestExpense
26837
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
31617
CY2017Q1 us-gaap Interest Paid
InterestPaid
20162
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
891541
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4186843
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
10583091
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-5091121
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5095901
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4780
CY2017Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4876
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4876
CY2017Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
3151867
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11592
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10583091
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4055000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3369023
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
858096
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13797312 shares
CY2018Q1 dei Amendment Flag
AmendmentFlag
false
CY2018Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
3869
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
868415
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3380128 shares
CY2018Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-9822
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
940204
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8395617
CY2018Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q1 us-gaap Depreciation
Depreciation
11406
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2018Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2018Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-8397063
CY2018Q1 dei Document Type
DocumentType
10-Q
CY2018Q1 dei Document Period End Date
DocumentPeriodEndDate
2018-03-31
CY2018Q1 dei Entity Registrant Name
EntityRegistrantName
ALDEYRA THERAPEUTICS, INC.
CY2018Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001341235
CY2018Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1891303
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-421037
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
617926
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
647931
CY2018Q1 us-gaap Interest Expense
InterestExpense
28044
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
122390
CY2018Q1 us-gaap Interest Paid
InterestPaid
22682
CY2018Q1 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>NATURE OF BUSINESS</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> Aldeyra Therapeutics, Inc. (the Company or Aldeyra), a Delaware corporation, is developing next-generation medicines to improve the lives of patients with immune-mediated diseases.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The Company&#x2019;s principal activities to date include raising capital and research and development activities.</p> </div>
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
4801481
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7954593
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4093316
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8491409
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
94346
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1446
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1446
CY2018Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
4009513
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
139006
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4093316
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
8950000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6600106
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
868415
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M3D
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.00 pure
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.50
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
819999 shares
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2018Q1 dei Trading Symbol
TradingSymbol
ALDX
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19366790 shares
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with US&#xA0;GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#x2019;s financial statements relate to accruals, including research and development costs, accounting for income taxes and the related valuation allowance and accounting for stock based compensation and the related fair value. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p> </div>
CY2018Q1 aldx Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
0 shares
CY2018Q1 aldx Number Of Incentive Plans
NumberOfIncentivePlans
3 Incentive_Plan
CY2018Q1 aldx Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice
0
CY2018Q1 aldx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00 pure

Files In Submission

Name View Source Status
0001193125-18-164070-index-headers.html Edgar Link pending
0001193125-18-164070-index.html Edgar Link pending
0001193125-18-164070.txt Edgar Link pending
0001193125-18-164070-xbrl.zip Edgar Link pending
aldx-20180331.xml Edgar Link completed
aldx-20180331.xsd Edgar Link pending
aldx-20180331_cal.xml Edgar Link unprocessable
aldx-20180331_def.xml Edgar Link unprocessable
aldx-20180331_lab.xml Edgar Link unprocessable
aldx-20180331_pre.xml Edgar Link unprocessable
d576126d10q.htm Edgar Link pending
d576126dex311.htm Edgar Link pending
d576126dex312.htm Edgar Link pending
d576126dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending